

**To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial**

Begemann MJH, Thompson IA, Veling W, Gangadin SS, Geraets CNW, van 't Hag E, Müller-Kuperus SJ, Oomen PP, Voppel AE, van der Gaag M, Kikkert MJ, van Os J, Smit HFE, Knegtering RH, Wiersma S, Stouten LH, Gijsman HJ, Wunderink L, Staring ABP, Veerman SRT, Mahabir AGS, Kurkamp J, Pijnenborg GHM, Veen ND, Marcelis M, Grootens KP, Faber G, van Beveren NJ, Been A, van den Brink T, Bak M, van Amelsvoort TAMJ, Ruissen A, Blanke C, Groen K, de Haan L, Sommer IEC.

Trials

2020; 21(1):e147

**ARTICLE IDENTIFIERS**

DOI: 10.1186/s13063-019-3822-5

PMID: 32033579

PMCID: PMC7006112

**JOURNAL IDENTIFIERS**

LCCN: 2006243052

pISSN: not available

eISSN: 1745-6215

OCLC ID: not available

CONS ID: not available

US National Library of Medicine ID: 101263253

This article was identified from a query of the SafetyLit database.